Open Access

Erratum to: Prognostic impact of CXCL16 and CXCR6 in non-small cell lung cancer: combined high CXCL16 expression in tumor stroma and cancer cells yields improved survival

  • Sigurd M. Hald1Email author,
  • Yury Kiselev3, 6,
  • Samer Al-Saad3, 5,
  • Elin Richardsen3, 5,
  • Charles Johannessen3,
  • Marte Eilertsen1,
  • Thomas K. Kilvaer2,
  • Khalid Al-Shibli3, 4,
  • Sigve Andersen1, 2,
  • Lill-Tove Busund3, 5,
  • Roy M. Bremnes1, 2 and
  • Tom Donnem1, 2
BMC Cancer201616:916

https://doi.org/10.1186/s12885-016-2954-1

Received: 14 November 2016

Accepted: 14 November 2016

Published: 24 November 2016

The original article was published in BMC Cancer 2015 15:441

Erratum

After publication of the original article [1], the author noticed that there are some error with Table 2 and Table 3. Please see the correct Tables below. We apologize for any inconvenience caused.
Table 2

CXCL16 and CXCR6 expression as predictors of disease-specific survival in 335 NSCLC patients

Characteristics

Patients, N (%)

Median survival (months)

5-year survival (%)

P

CXCL16

 Cancer cells

   

.080

  High

48 (14)

NR

67

 

  Low

227 (68)

98

56

 

  Missing

60 (18)

   

 Stromal cells

   

.016

  High

258 (77)

189

62

 

  Low

43 (13)

57

48

 

  Missing

34 (10)

   

CXCR6

 Cancer cells

   

.093

  High

41 (12)

190

73

 

  Low

245 (73)

122

55

 

  Missing

49 (15)

   

CXCL16

 Cancer cells + stromal cells combined

   

.016

  High/High

43 (13)

NR

71

 

  High/Low

182 (54)

190

58

 

  Low/Low

41 (12)

47

48

 

  Missing

69 (21)

   

NR, not reached; NCSLC, non-small cell lung cancer. Bold values indicate p < 0.05

Table 3

Results of multivariate Cox regression analyses for clinicopathological factors and CXCL16 in stromal cells (model 1) and co-expression of CXCL16 in cancer and stromal cells (model 2*)

Factor

HR

CI 95%

P

T-status

  

<0.001

 T1

1.00

  

 T2

1.60

(0.97-2.64)

0.065

 T3

3.80

(2.13-6.77)

<0.001

N-status

  

<0.001

 N0

1.00

  

 N1

2.01

(1.30-3.11)

0.002

 N2

3.08

(1.74-5.44)

<0.001

Differentiation

  

0.009

 Well

1.00

  

 Moderate

1.17

(0.63-2.20)

0.618

 Poor

2.08

(1.12-3.85)

0.020

Performance status

  

0.040

 ECOG 0

1.00

  

 ECOG 1

1.52

(1.02-2.26)

0.040

 ECOG 2

2.15

(0.94-4.91)

0.069

Vascular infiltration

   

 No

1.00

  

 Yes

1.70

(1.01-2.87)

0.046

Histology

  

<0.001

 Squamous carcinoma

1.00

  

 Adenocarcinoma

2.23

(1.48-3.35)

<0.001

 Large cell carcinoma

0.80

(0.39-1.66)

0.555

CXC16 stromal cells

   

 Low

1

  

 High

0.55

(0.35-0.87)

0.011

CXCL16 cancer and stromal cells*

  

0.031

 Low/Low

1.00

  

 Low/High + High/Low

0.57

(0.35-0.93)

0.023

 High/High

0.42

(0.20-0.88)

0.022

Overall significance as prognostic marker. HR, Hazard ratio. Bold values indicate p < 0.05

Notes

Declarations

Open AccessThis article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.

Authors’ Affiliations

(1)
Department of Clinical Medicine, UiT The Arctic University of Norway
(2)
Department of Oncology, University Hospital of North Norway
(3)
Department of Medical Biology, UiT The Arctic University of Norway
(4)
Department of Pathology, Nordland Hospital
(5)
Department of Clinical Pathology, UniversityHospital of North Norway
(6)
Department of Pharmacy, UiT The Arctic University of Norway

References

  1. Hald SM, et al. Prognostic impact of CXCL16 and CXCR6 in non-small cell lung cancer: combined high CXCL16 expression in tumor stroma and cancer cells yields improved survival. BMC Cancer. 2015;15:441. doi:10.1186/s12885-015-1446-z.View ArticlePubMedPubMed CentralGoogle Scholar

Copyright

© The Author(s). 2016

Advertisement